The German pharmaceutical company Medac, in August, will begin Phase 3 of a clinical trial to access the therapeutic potential of terguride, a disease–modifying drug for the treatment of diffuse cutaneous systemic sclerosis. Scleroderma News, 06/09/2016. (Also see Scleroderma Clinical Trials)
This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.